AGP Explained: Brands, Plants and Acquisitions

Company Name: AGP Ltd

Ticker: AGP

AGP is a Pakistani pharmaceutical manufacturer, marketer and brand-acquisition platform. It earns by turning registered molecules and acquired brand rights into locally manufactured or traded medicines, then using a large field force and nationwide distribution to reach pharmacies, hospitals, physicians and patients. The group spans anti-infectives, internal medicine, women’s health, cardiometabolic care, neuropsychiatry, nutrition and specialty products.

The simple version is “make and sell medicines.” The better version is that AGP manages five linked assets: regulatory approvals, trusted brands, manufacturing capability, commercial relationships and working capital. Manufacturing protects availability and gross margin; brands support prescription demand; acquired portfolios expand scale; distribution converts demand into orders; and cash collection funds inventory, marketing and debt. Reported facts below are sourced. Management plans and merger projections are identified as such. AlphaGen inference means an economic interpretation, not company guidance or investment advice.

What AGP does

The Pakistan Stock Exchange profile describes AGP’s activities as importing, marketing, exporting, dealing, distributing, wholesaling and manufacturing pharmaceutical products. That unusually broad legal description reflects the real model. Some medicines are made in AGP facilities, some are acquired or licensed brands, and some are traded products. The group can therefore monetize a product without owning every stage of its original development.

AGP began commercial operations in 1989. Its official history records an early joint venture with Eli Lilly for cephalosporins, a manufacturing and marketing agreement with UCB Belgium, later purchases of the rights to Ceclor, Keflex, Kefzol, Nebcin and Rigix, and a 2016 marketing agreement with Mylan. It listed on PSX in 2018, acquired a nutraceutical plant in 2019, acquired 22 Sandoz brands through OBS AGP in 2021 and 17 former Viatris/Pfizer brands through OBS Pakistan in 2023.

Portfolio: breadth reduces dependence on one therapy

The June 2026 corporate briefing describes 135 brands and more than 280 stock-keeping units across AGP and its subsidiaries, with 30 product launches during the preceding five years. The portfolio covers branded pharmaceuticals, generics, nutraceuticals and specialty healthcare. Management also highlighted newer commercial rights for STADA products and rights to commercialize and promote Xanax and Viagra.

The company’s public portfolio spans internal medicine, gynaecology, paediatrics, orthopaedics, cardiometabolic care and neuropsychiatry. Examples on its official product pages include Ceclor and Kefzol antibiotics, Rigix for allergy, Osnate mineral preparations, anti-epileptics and iron products. The point is not any single brand recommendation. Economically, acute anti-infectives respond to infection seasons, while chronic therapies can create repeat demand; women’s health and nutraceuticals add different prescriber and consumer channels.

Plants, dosage forms and the production process

AGP’s official company profile lists three Karachi facilities: Plant I and the head office at SITE, Plant II at SITE, and Plant III at SITE Super Highway Phase II. The 2026 management presentation calls these three cGMP plants. Plant I and Plant II hold manufacturing licences 348 and 44 respectively.

The company’s quality-management description says its facilities can make tablets, capsules, syrups, suspensions, sachets, liquid parenterals and semi-solid preparations. Production begins with approved active pharmaceutical ingredients, excipients and packaging materials. Materials are received and tested; ingredients are weighed, mixed, granulated or compounded; dosage forms are compressed, filled or packed; batches undergo in-process and finished-product testing; and quality assurance releases compliant lots.

Raw materials, imports and energy dependencies

The largest direct input is raw and packing material. In standalone Q1 2026 cost of sales, AGP consumed PKR 1.799 billion of raw and packing materials, while manufacturing salaries were PKR 407.5 million and fuel, gas and electricity were PKR 106.7 million, according to the official first-quarter report. Repairs, processing, freight, laboratory work and depreciation formed additional conversion cost.

Active ingredients and specialized excipients may be imported or sourced locally depending on molecule, registration and qualified suppliers. Packaging includes cartons, inserts, bottles, foils, blisters and labels. Because the report does not publish a supplier-by-supplier import ratio, a precise localization percentage would be speculation. What is clear is that foreign currency, freight, lead times, letters of credit and regulatory change can affect landed cost and availability.

At 31 March 2026, standalone stock-in-trade was PKR 4.440 billion. Raw and packing material in hand and in transit represented PKR 3.363 billion, much more than finished manufactured and traded goods of PKR 806.4 million. Management says it is localizing procurement where possible, diversifying sources and maintaining buffers. That can protect supply, but too much buffer raises cash and obsolescence risk.

Customers and route to market

Muller & Phipps Pakistan is a major distributor and related party. Q1 2026 standalone sales to it were PKR 2.664 billion, and the quarter-end receivable from it was PKR 1.218 billion. The arrangement provides national reach but also creates visible distributor concentration in receivables. Group-company supplies form another route: management said Q1 standalone growth included deliveries to subsidiaries and affiliates.

Exports diversify geography and bring foreign currency. AGP’s official export page lists Afghanistan, Sri Lanka, Kenya, Botswana and Cambodia and says the company is exploring Francophone, Central American, Far East Asian and CIS markets. In Q1 2026, standalone gross export revenue rose to PKR 1.542 billion from PKR 610.8 million, while local manufacturing and trading revenue was almost flat before discounts. Management identified Afghanistan exports as a major growth driver.

Pricing, regulation and quality

Medicines are not priced like an unregulated consumer good. The Drug Regulatory Authority of Pakistan oversees licensing, registration, quality, safety and therapeutic-goods regulation, while its public price index records approved product prices and effective dates. Pricing flexibility differs by category and policy, and registration changes can take time.

AGP’s margin is therefore the spread between approved or commercially achievable net price and material, conversion, distribution and promotion cost. A rupee depreciation can raise material cost faster than prices adjust. Conversely, price revisions, localization, better product mix or manufacturing yield can widen margin.

Quality failures can destroy more value than a normal cost overrun because they can trigger recalls, lost confidence and regulatory action. Counterfeiting creates a related but distinct risk. On 17 July 2026, AGP issued an official clarification that a Punjab alert concerned counterfeit Azomax recovered outside its authorized supply chain, not genuine AGP product. The disclosure says AGP checked packaging, security features, serialization and manufacturing specifications. This is a company clarification supported by the attached government alert; it illustrates why traceability and authorized distribution matter.

How revenue and margins are built

Revenue equals packs sold multiplied by net realized price after trade discounts, returns and sales tax. In Q1 2026, AGP’s standalone gross revenue was PKR 6.178 billion, but discounts, returns and sales tax reduced it by PKR 791.5 million to PKR 5.387 billion. Trade discounts alone almost doubled to PKR 714.6 million. Readers should therefore watch net revenue, not headline gross billing.

Standalone Q1 net revenue rose 11.9% to PKR 5.387 billion. Gross profit rose 14.5% to PKR 2.492 billion, lifting gross margin to 46.26% from 45.20%. Marketing and selling expense rose 9.0% to PKR 1.179 billion; finance cost rose 20.4% to PKR 128.5 million; and profit after tax rose 19.6% to PKR 556.9 million. EPS was PKR 1.99.

The group model: subsidiaries and acquired portfolios

The consolidated group includes AGP Limited, 65%-owned OBS AGP and 91.82%-owned OBS Pakistan. OBS AGP holds the former Sandoz portfolio; OBS Pakistan holds former Viatris/Pfizer brands. The standalone accounts carry these investments at PKR 3.074 billion, while consolidated accounts combine their operations and allocate part of profit to non-controlling shareholders.

This distinction is material. FY2025 standalone revenue was PKR 20.546 billion and profit after tax PKR 2.360 billion. Consolidated revenue was PKR 28.890 billion, profit after tax PKR 4.335 billion and profit attributable to AGP shareholders PKR 3.735 billion, according to the FY2025 annual report and management’s 2026 briefing. A reader valuing the listed company should use consolidated economics but distinguish total profit from the portion attributable to AGP owners.

Acquired trademarks are economically important. At 31 March 2026 the consolidated balance sheet carried about PKR 16.67 billion of indefinite-life trademarks, compared with PKR 4.64 billion in the standalone company. Brands can earn for many years, but indefinite-life assets must be tested for impairment. If acquired products underperform, the accounting value and expected acquisition return can both come under pressure.

Proposed merger: simplification with execution risk

Management has proposed a group reorganization that would combine the business assets of Aitkenstuart, AGP, OBS AGP, OBS Pakistan and OBS Pharma into AGP, while Aspin would remain under the post-merger structure. The June briefing says the scheme is subject to shareholder, creditor and regulatory approvals and sanction by the High Court of Sindh. It should therefore be treated as proposed until legally effective.

Management’s case is operational: consolidate manufacturing, distribution and supply chains; add hormonal and psychotropic capability; remove toll-manufacturing margin splits; combine commercial teams; reduce duplicate compliance cost; and broaden women’s health, dermatology and consumer healthcare. OBS Pharma originated from a 2023 Bayer portfolio and plant acquisition and had management-reported CY2025 revenue of about PKR 8.7 billion and profit after tax of about PKR 1.4 billion.

The trade-off is dilution and debt. The presentation models issued shares rising from 280.0 million to about 388.7 million and long-term debt rising from PKR 8.2 billion to PKR 15.9 billion on pro-forma December 2025 numbers. Management projects synergies and deleveraging, but projections are not facts. The merger creates value only if incremental cash earnings and cost savings exceed financing, integration, dilution and execution cost.

Cash conversion and capital intensity

AGP’s Q1 standalone profit before working-capital changes was PKR 1.228 billion, yet cash generated from operations fell to PKR 66.4 million because trade debt increased by PKR 1.131 billion and advances increased by PKR 166.4 million. After finance cost and tax, operating cash outflow was PKR 358.8 million. Short-term borrowing increased to PKR 2.588 billion from PKR 1.836 billion at December 2025.

This is the key cash lesson. Prescription demand and accounting revenue do not immediately equal cash. Product may be sold to distributors or group entities on credit while materials, payroll, promotion and taxes are paid. Strong earnings quality therefore requires receivables and inventory to grow slower than sales over a full cycle.

Competitive position and favourable conditions

AGP’s structural strengths are established brands, multiple dosage forms, three plants, multinational licensing history, nationwide distribution, export registrations and a repeatable acquisition model. Portfolio diversity and gross margins above many commodity manufacturers provide room to absorb commercial expense. The group also benefits from chronic-care demand and the defensive nature of essential healthcare.

Its constraints are imported-input and FX exposure, regulation, quality risk, aggressive competition for prescriptions, high selling intensity, distributor concentration, working-capital needs and acquisition debt. Brand acquisitions can lift growth quickly but also create goodwill, trademark and integration risk.

The favourable environment is stable currency and freight, timely raw-material imports, rational pricing, reliable energy, strong prescription demand, successful launches, low receivable days and falling interest rates. The adverse environment combines rupee weakness, supply disruption, delayed regulatory approvals, price-cost mismatch, counterfeit or quality events, distributor destocking, rising borrowing cost and an acquisition that fails to deliver expected cash flows.

Growth avenues

AGP can grow by increasing domestic market share of established brands, launching line extensions, commercializing licensed products, exporting existing dossiers, localizing inputs, raising plant utilization and integrating acquired portfolios. The merger could add women’s health and specialized manufacturing at larger scale. Exports provide a partial currency hedge, while localization can reduce exposure to imported cost.

Key facts and figures

1. Operating history: commercial operations began in 1989; PSX listing occurred in March 2018. Source

2. Manufacturing footprint in 2026: three Karachi plants; Plant I and II hold manufacturing licences 348 and 44. Source

3. Group portfolio disclosed in June 2026: 135 brands, more than 280 SKUs and 30 launches over five years. Source

4. FY2025 consolidated revenue: PKR 28.890 billion; five-year revenue CAGR stated by management: 33%. Source

5. FY2025 consolidated profit after tax: PKR 4.335 billion; attributable to AGP owners: PKR 3.735 billion. Source

6. Q1 2026 standalone revenue: PKR 5.387 billion; profit after tax: PKR 556.9 million; EPS: PKR 1.99. Source

7. Q1 2026 consolidated revenue: PKR 6.850 billion; profit after tax: PKR 968.0 million; attributable profit: PKR 857.0 million. Source

8. Q1 2026 consolidated gross margin: 58.3%, compared with 57.6% in Q1 2025. Source

9. Standalone stock-in-trade at March 2026: PKR 4.440 billion, including PKR 3.363 billion of raw and packing materials. Source

10. Standalone trade receivables at March 2026: PKR 2.392 billion, up from PKR 1.262 billion at December 2025. Source

11. Q1 2026 standalone operating cash outflow: PKR 358.8 million despite PKR 556.9 million accounting profit. Source

12. Standalone property, plant and equipment at March 2026: PKR 5.179 billion; capital work in progress: PKR 551.1 million. Source

13. Consolidated indefinite-life trademarks at March 2026: PKR 16.666 billion. Source

14. Proposed post-scheme shares: approximately 388.7 million versus 280.0 million existing; subject to approvals. Source

15. Current export markets listed by the company in 2026: Afghanistan, Sri Lanka, Kenya, Botswana and Cambodia. Source

How to read this company’s results

Start by choosing the correct basis. Use consolidated revenue, operating profit, debt and cash flow to understand the economic group. Then use profit attributable to AGP shareholders and EPS for the listed owners. Standalone figures explain AGP’s own plants and sales, but they omit much of the acquired-brand economics.

Second, split revenue into local manufacturing, local trading and exports, then reconcile gross billing to net revenue after discounts and returns. Compare gross margin with raw-material cost and currency movement. A higher price is not automatically better if discounts or imported inputs absorb it.

Third, measure commercial productivity. Track marketing and selling expense as a percentage of revenue, new-product contribution and growth of major brands. Pharmaceutical promotion is necessary, but sustained growth should eventually create operating leverage.

Fourth, reconcile profit to cash. Watch receivables—especially distributor and group balances—inventory, advances, payables and short-term borrowing. If profit rises while operating cash remains weak, investigate collection and inventory rather than assuming earnings quality.

Finally, treat merger numbers as scenarios until the scheme becomes effective. After completion, compare actual share count, acquired debt, integration cost, savings, cash flow and attributable EPS with management’s pro-forma case. The decisive question is whether a larger portfolio produces more cash per share after financing and dilution.

What readers should monitor next

Monitor local manufacturing growth, exports, gross-to-net discounts, gross margin, selling expense, receivable days, raw-material inventory, short-term borrowing, finance cost, product launches, regulatory actions, quality events and merger approvals. For acquisitions, track attributable profit, operating cash flow and impairment indicators—not revenue alone.